Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Gastroesophageal reflux disease is a frequent disease and which heavily affects the patients' quality of life. To alleviate symptoms and ease the healing of lesion, patients very often need to continuously take anti-secretory drugs (Proton pump inhibitors or PPIs), which, despite their efficiency, do not cure the disease. For these PPI dependent patients, an anti-reflux surgery (fundoplication often made by coelioscopy) is a possible alternative but it has a significant morbidity rate and even an estimated post-operative mortality of 0.8% outside of expertise centres. Therefore, new therapeutic endoscopic approaches, supposed to be less invasive and less expensive than surgery have been developed during the last three years. Among them, radiofrequency (Stretta® procedure) consists in administering a high frequency current in the cardia area, in order to induce thanks to a thermal effect a sub-mucous remodelling and a modification of the compliance of the cardia regionThe aim of this project carried out in 8 French centres and 2 European centers is to assess through a randomised trial, the efficiency of radiofrequency on PPI dependent patients. The study will be carried out in 2 phases with patients who have been fully informed of the project statement, and particularly of the potential risks of the radiofrequency technique and have given their written acceptation to participate to the study.The first phase, which will last 6 to 11 weeks, will aim at making sure that patients are PPI dependent and define their needs. After this initial phase, patients will be randomised between those who will carry on with the PPI treatment or the radiofrequency treatment. The follow up after this randomisation will last one year. The first assessment of the therapeutic efficiency will be done at 6th month. The 6 additional follow up months will be required for the assessment of mid-term side effects of the treatment and the rate of symptomatic recurrences.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient above 18 years old
Suffering from typical symptoms of reflux (heartburn and/or acid regurgitation and/or epigastric burns with ascending radiations)
Symptoms occurring at least 3 times a week without treatment
Symptoms disappearing under full doses PPI treatment
Requiring a continuous treatment for more than 3 months to get rid of symptoms (or nearly)
Total consent signed from patient
Contraindications to the radiofrequency technique:
Columnar lined oesophagus ³ 3 cm height
Barret's mucosa presenting dysplasia
History of treated columnar lined oesophagus
Hiatus hernia with a size over 3 cm
History of Stage C or D esophagitis in the Los Angeles classification (18), or in progress
History of oesophageal stenosis
History of gastric or oesophageal surgery
Presence of oesophageal and/or cardial varicose veins
Presence of a cardiac pacemaker or implanted defibrillator (when confirmed by the manufacturer that use of RF energy will not interfere, it's ok to do patients!)
Impossibility to interrupt a anticoagulant treatment or serious disorders of haemostasis
Contraindication to general anaesthesia
Existence of an associated serious disease making fear that the patient will live less than a year
Incapacity to understand and sign a sensible consent of participation to the study
Chronic alcoholism defined by a daily consumption of alcohol over 60 g
Morbid obesity defined by a rate of body mass higher that 35
Patients suffering from atypical GERD symptoms (especially extra-digestive) will not be included in the study if these symptoms are not associated with typical reflux symptoms (heartburn or regurgitation)